Skip to Content

WPI 900 (Glipizide Extended Release 2.5 mg)

Pill with imprint WPI 900 is Yellow, Round and has been identified as Glipizide Extended Release 2.5 mg. It is supplied by Watson Pharmaceuticals.

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 2.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 900

Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900  Front
Glipizide extended release 2.5 mg WPI 900  Back
Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900

Glipizide Extended Release

Imprint:
WPI 900
Strength:
2.5 mg
Color:
Yellow
Shape:
Round
Availability:
Prescription only
Drug Class:
Sulfonylureas
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Watson Pharmaceuticals
Inactive Ingredients:
acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
lactose monohydrate
magnesium stearate
methacrylic acid - methyl methacrylate copolymer (1:1)
polyethylene glycol
FD&C Yellow No. 6
shellac
isopropyl alcohol
ferrosoferric oxide
butyl alcohol
propylene glycol
ammonia
Note: Inactive ingredients may vary.

Other Labelers / Repackagers:

NDC CodeLabeler / Repackager
68084-0295 Amerisource Health Services

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide